Gallbladder disease risk — cholelithiasis data from clinical trials

The figures, for anyone assembling their own picture. A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator. Three questions, and they resolve most disagreements in these threads.

A narrower follow-up, since the general answer is now clear:

How to read a result like this without either dismissing it or over-reading it, since the summaries all read like press releases?

HPLC_Greg said:

A quick sanity check on any figure quoted here: is it mean or median, is it intention-to-treat or completers, and what was the comparator.

Adding the part of the answer the thread has not reached. The gap between trial results and real-world results is consistent and it is not fraud. Trial participants get titration by protocol, scheduled contact, free drug and dietetic support; removing that infrastructure costs a few percentage points every time it has been measured. When your own curve sits below the published mean, that is the likeliest explanation before anything about you or your material.

Closing the loop on my own question.

Update — my curve sits below the published mean and the explanation is that the trial arm had support I do not have. That was reassuring rather than otherwise.

Dr.PainCLE said:

The gap between trial results and real-world results is consistent and it is not fraud.

Gallbladder warning for gallbladder risk: rapid weight loss increases gallstone risk regardless of method. GLP-1 patients have a ~2-3% incidence of gallbladder events in clinical trials.

Symptoms to watch for: pain in upper right abdomen after fatty meals, nausea after eating, pain radiating to right shoulder. I had my gallbladder out at month 6 — it was full of stones. My surgeon said it's very common in significant weight loss patients.